FGF23 and X-linked hypophosphatemia: Therefore, information on the effect of long-term burosumab treatment and the impact of the age of initiation will be important in understanding the role burosumab can play in treating the wider symptomatology of XLH and, in addition, will also provide insights into which disease features cannot be addressed by targeting FGF23.